News

Published:

April 23, 2015
 
Tagged: Derner School of Psychology, Day Residue

Faculty Spotlight: Denise A. Hien, Ph.D.

News, Newsletter


 

Day Residue Spring 2015By Lauren Knopf, M.A.

Dr. Denise Hien has conducted programmatic research on women’s mental health, trauma and addiction for over 20 years. Having taught at Adelphi early in her career in the late 1990s, she returns to Derner this spring, bringing a wealth of knowledge on evidence-based treatments for trauma-related psychiatric disorders and comorbid addictions.

LK: What made you decide to return to Derner?

DH: I felt that what’s happening at Derner now is very much synergistic to where I am in my life and my interests. It’s a place that’s creating new energy around psychotherapy research, in particular, dynamically oriented research. It’s exciting to be around other people who are successful and interested in the kind of work that I do. There’s also faculty doing work in trauma and in psychotherapy research, and then there’s the interest in addiction, which is the new piece I’m able to bring to the mix. So there were a number of converging factors that made it feel like it was a good time to come back to Adelphi.

LK: I can imagine there are tremendous differences in the doctoral program at Derner now compared to what it was when you first worked at Adelphi in 1995.

DH: Certainly, although I’ve changed in 20 years, too! I think that the program has only gotten stronger. From the APA point of view, I think Derner has made changes in order to retain a strong clinical and dynamic orientation and appreciation, but at the same time to adopt a more integrated perspective. I think teaching students to value other perspectives is really important in today’s marketplace. That’s something that I think has been hard for dynamically oriented programs to do. Either you completely change and become a CBT shop, or you get entrenched in an attitude of, “This is the only way to think.”

LK: It seems like that type of attitude is antithetical to the type of research you have done.

DH: I’m an integrative person who was trained from a dynamic perspective. The work that I do is very much focused on how past and present can co-exist. Trauma theory tends to be non-discipline specific and draws on an interdisciplinary perspective, which is one thing that drew me to the field. But I think historically researchers and practitioners have had a perspective that keeps them from realizing how many common factors there are across treatments. Even the most adherent CBT practitioner still will get to know a patient’s past and how it might be active in the present. And there’s a therapeutic alliance that drives all treatments—we know that from all of the research that’s been done. The techniques are important too, but not as important. The most powerful element is the relationship

LK: Many of your studies of treatments for women with a history of trauma and comorbid addictions have found support for the self-medication model of substance abuse. In your experience, is trauma implicated in the majority of addictions, or are there other important factors?

DH: The causes of addiction are multifaceted. For some people, having an early trauma history is probably a causal factor in developing a substance use disorder. That’s not to say that anyone who is exposed to trauma will develop a substance use disorder, but it is one mechanism by which that happens. There’s a lot of science that shows that trauma changes the brain in particular ways that make it more likely to succumb to the need for reward and activation. From a psychological perspective, it makes perfect sense that your emotional experiences could impact the likelihood that you would use a substance to selfsoothe. Recently there was a study called the ACES [Adverse Childhood Experiences] study, conducted jointly by the CDC and Kaiser Permanente, looking at the relationship between childhood adversity and the development of all different sorts of problems, addiction being one of them. This work has showed definitively that there is a clear cut, almost linear relationship between the number of exposures to traumatic child events and the development of all kinds of negative health outcomes, including addiction, obesity, and premature mortality. The majority of women who end up in treatment for drug addiction have significant childhood and ongoing trauma, interpersonal violence histories and addictions. For them, PTSD, depression, anxiety or other trauma-related pathology is part of the clinical picture of addiction.

LK: Seeking Safety is one trauma-focused addiction intervention that has significant empirical support, but at times you’ve lamented that not all studies of Seeking Safety are as rigorous as they could be, leaving gaps in the empirical base. Where is the tipping point, when enough empirical evidence is amassed that an intervention is accepted as evidence-based?

DH: That’s a big question. Both Seeking Safety and Relapse Prevention are incredibly powerful interventions. What we’ve found is, whenever you set up a study where you’re comparing a treatment to another that is already really powerful, you’re not going to see a very big difference. This is disappointing to some researchers, who would say you should never compare your experimental treatment to an active treatment so you can achieve significant results. It’s interesting, because we don’t see this mindset when it comes to medications. If both Zoloft and Paxil are helpful, then fantastic! With medication, we want more options, more alternatives. I don’t know how this has happened, but in the psychotherapy world there has been a focus on finding the “one” treatment. Seeking Safety is a very good first line treatment, but does it solve all of the person’s problems? No. Might patients need other things in addition, whether it’s another type of trauma treatment, or longer treatment, or medication? Yes, they need all of those things. These are very sick people who have had horrible things happen in their lives. A dose of 12 sessions of anything isn’t going to fix things for them.

LK: Do you think this desire to find the “one” treatment is waning? DH: I hope so. I know it’s waning for me. The work I’m doing now is all about personalized and individualized approaches about understanding what works for whom, when does it work, how does it work, when does it not work? I’m interested in the whole gamut of questions other than, “Which treatment is better?” This, to me, is a boring question and really sort of sets us up for failure. For me, research is about helping guide us along the path. Neither research nor clinical work alone is going to give us all the answers about how to treat the human heart and mind. It’s more like can we get some beacons of light to guide us in the darkness. A research study, if we do it well enough, can give us some guidance.

LK: What is one of your most interesting findings to date?

DH: I was involved in a research project years ago at St. Luke’s Roosevelt Hospital. We were fortunate to have access to every single mental health service available at the hospital for our project—inpatient, outpatient, child psychiatry, day programs, and addiction services. We conducted SCID evaluations with patients in each of the separate mental health units, and we found that all patients were the same. About 50% of the patients in mental health settings had diagnosable addiction problems and about 50% of those in substance use settings also qualified for other mental health diagnoses. This demonstrated very clearly that dividing people with addictions and people with mental health disorders into separate clinical populations is quite arbitrary. If we know that 50% of patients have co-morbid disorders, then we can see that co-morbidity is not the aberration, it’s the norm.

LK: You mentioned earlier that your interest now is which treatments work for whom. Is this research done less frequently than comparison studies because it is too labor intensive, or because there is a methodological bias?

DH: Well, actually I think we’ve come full circle. Lately the NIH has expressed significant doubts about the value of what the single site clinical trial can achieve. Single site clinical trials take a lot of time and cost a lot of money, and at the end of the day there are questions about how generalizable the findings of any one small scale study are. Right now, I’m working on a grant with colleagues that we’re calling the “virtual multisite clinical trial.” This method allows us to pool a large number of single site studies together and use innovative statistical modeling techniques to ask even more nuanced questions than the typical multi-site trial. I’m very excited about it, and I feel like it’s a direction that avoids the limitations of a traditional clinical trial, while making use of all of the work that others have already done and taking it to the next level.

LK: I have to admit that makes me feel better about research in general, that we can make use of existing data in a way that will support this more detailed approach of determining what works best for different subsets of patients.

DH: Making use of research has motivated all of my work. Clinical theory has influenced the way I think about the research that I do, and vice versa. I live a bidirectional life in that regard, and it’s a good thing. The research that I’ve done has also been that way in terms of deriving the ideas from community-based practices, participating in the development of the research ideas, the conduct of the research and then giving back at the end of the day. It’s very rewarding to be able to communicate with and to influence people working in the field so that research is not just done in an Ivory Tower by people who have no knowledge of what it’s like to work with actual patients in the real world. The type of studies I strive to do honor the fact that whatever you do in the lab should have relevance in the real world.

 

Published April 2015 in Day Residue, the Derner Institute Doctoral Student Newsletter
 
Tagged: Derner School of Psychology, Day Residue